Filing Flows › Anika Therapeutics (ANIK) › Free cash flow
Anika Therapeutics (ANIK) free cash flow by quarter
Anika Therapeutics' free cash flow was $6.7M in Q3 2026 (third quarter 2026), +68% from Q4 2025. Over the last 3 quarters it ranged from $4.0M (Q4 2025) to $6.7M (Q3 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $6.7M | +68% | +35% |
| Q4 2025 | $4.0M | -20% | — |
| Q3 2025 | $5.0M | — | — |
Q3 2026 at a glance
Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Anika Therapeutics' free cash flow?
Anika Therapeutics' free cash flow was $6.7M in Q3 2026 (third quarter 2026), +68% from Q4 2025.
How has Anika Therapeutics' free cash flow changed?
Over the last 3 quarters it ranged from $4.0M (Q4 2025) to $6.7M (Q3 2026).